Trevi Therapeutics slips on $100 mln stock sale plans
View all comments(0)
Shares of Trevi Therapeutics TRVI.O down 3.6% in extended trading to $6.09 as co plans equity raise
New Haven, Connecticut-based firm commences $100 mln stock offering
Morgan Stanley. Leerink, Stifel and Cantor are jt bookrunners
Before the bell on Mon, co announced positive topline results from Phase II trial of its therapy, Haduvio, for patients with a type of chronic cough, and said plans Phase III initiation in 2026
With ~101.7 mln shares outstanding, co has about $680 market cap, per LSEG data
TRVI closed down 3% at $6.32 on Mon, trimming YTD gain to 53%
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Hantavirus Appears Sporadically, Is Now the Opportunity to Buy Vaccine Concept Stock Moderna?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.